Replies to post #409985 on Amarin Corp Plc (AMRN)

[Whalatane]

Zip ..its not only about price
From BARD

The German Health Department (GHV) requires at least two independent clinical trials proving efficacy before approving reimbursement for a new cardiovascular risk reduction drug. The trials must be randomized, controlled, and double-blind. They must also be conducted in a large enough population to be statistically significant.

The GHV also requires that the trials meet certain quality standards. For example, the trials must be well-designed and well-conducted. The data must be collected and analyzed in a rigorous manner. And the results of the trials must be reproducible.

If the GHV is satisfied that the trials meet all of the required standards, it will approve reimbursement for the new drug. The drug will then be available to patients through the German health insurance system.

It is important to note that the GHV's requirements for reimbursement are constantly evolving. As new drugs and treatments are developed, the GHV may update its requirements to ensure that patients have access to the best possible care.

Kiwi